The Mount Sinai Tisch Cancer Center has launched a new artificial intelligence (AI) platform to help connect more cancer patients across the Mount Sinai Health System to life-saving clinical trials. The platform, which was created by the AI company Triomics, is called PRISM, and is powered by Triomics’ OncoLLM, a large language model-based pipeline built especially for cancer care. The deployment marks a major step forward in expanding access to innovative cancer research, accelerating clinical trial enrollment, and ensuring patients across the Health System are considered for cutting-edge treatment options earlier in their care. Press release. 

Medable announced its TMF Agent, which brings AI and automation to the labor-intensive processes required for trial document management. It is built on Medable’s Agent Studio, the industry’s first agentic AI platform for clinical development. TMF Agent orchestrates TMF workflows end to end, autonomously ingesting documents from shared inboxes, drives, and other upstream sources, classifying files, extracting metadata, and preparing them for human review prior to one-click submission into commonly used eTMF systems, including Veeva Vault, Wingspan, and OpenText. Press release. 

N-Power Medicine and AdventHealth have entered a strategic collaboration to make clinical research more accessible for people receiving cancer care in their communities. Through this collaboration, AdventHealth will integrate N-Power’s Kaleido Registry and Prospective External Control Arm platform into routine oncology care at select locations across its cancer care network in Colorado, Kansas, Georgia, and Florida, beginning this month. The goal is to advance a more connected, patient-centered approach to oncology research. Press release. 

Fabentech has been granted marketing authorization for Ricimed, a treatment for ricin poisoning. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Ricimed is an antibody-based therapy relying on polyclonal antibodies, addressing the absence of any vaccine or specific treatment to date, and has demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs. Press release. 

Verana Health has merged with COTA. The combined companies will serve 17 of the top 20 global biopharma companies, with access to over 95 million patients and over 20,000 contributing clinicians, including expanded network access to more than 30 academic medical centers, increasing accessible oncology patients to over 10 million. Together, the companies will deliver deeper, more clinically rich real-world data and insights, supported by trusted, research-ready evidence designed to meet the rigor required for clinical and regulatory decision-making. This combination helps accelerate the leveraged, multitherapeutic area strategy that Verana Health has successfully delivered on. Press release. 

TrialAssure announced the opening of TrialAssure B.V., its new European office located in Eindhoven, Netherlands. The new Eindhoven location will serve as a strategic hub for collaborating with European pharmaceutical companies, research organizations, and regulators as transparency requirements continue to evolve. TrialAssure B.V. will focus on delivering the company’s full suite of data, document, and image anonymization, clinical trial registration and results disclosure, generative AI document development, and compliance solutions to clients throughout the region. Press release. 

UBC has acquired Evidinno. The acquisition strengthens UBC's leadership in evidence generation offerings with globally recognized expertise in HEOR, medical affairs, and market access. Evidinno will operate as a wholly owned subsidiary of UBC with an integrated combined offering that enhances UBC's ability to deliver full spectrum consulting and decision driving evidence across the clinical development and post approval continuum. Press release.